Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer

• Status: Terminated
• Trial end date: 2015-05-21
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial studies how well Polyphenon E works in treating patients with high-risk of colorectal cancer. Polyphenon E contains ingredients that may prevent or slow colorectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Epigallocatechin gallate

Criteria

Inclusion Criteria:

• Current or prior advanced adenomas. Participants with advanced adenomas are defined as participants who have polyps >= 1 cm, who have tubulovillous adenomas (25-75 percent villous features), who have villous adenomas (>75 percent villous), or who have severe dysplasia

• Prior curatively resected Tumor, Node, Metastasis (TNM) stage II and III colon cancer >= 3 years out from treatment by surgery with/without adjuvant chemotherapy; NOTE: patients with stage I (T1,2 N0) colon cancer treated by endoscopic or surgical therapy are eligible at anytime after such therapy; patients with prior stage IV disease must be >= 5 years status post surgical resection of all metastatic disease

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

• Ability to understand and the willingness to sign a written informed consent document

• Willingness to discontinue regular usage of calcium supplements; Exception:

multi-vitamin; regular use defined as a frequency of 7 consecutive days for > 3 weeks

• Willingness to provide mandatory tissue and blood for protocol specified research; residual tissue and/or blood may be used for future research Negative pregnancy test =< 7 days prior to registration/randomization

• Hemoglobin (Hgb) >= 12.0 g/dL (women), >= 13.5 g/dL (men) at Mayo Clinic or within normal limits at an outside laboratory

• Platelet count >= 100,000/ul

• White blood cells (WBC) >= 3,000/ul

• Alanine aminotransferase (ALT) within institutional limits of normal

• Alkaline phosphatase within institutional upper limit of normal (ULN)

• Aspartate aminotransferase (AST) within institutional limits of normal

• Total bilirubin within institutional limits of normal

• Serum calcium =< institutional ULN

• Serum creatinine =< 1.5 x institutional ULN

• >= 5 rectal ACF detected by chromoendoscopy =< 45 days prior to registration/randomization

• Endoscopy =< 45 days prior to registration/randomization; Note: All adenomas or polyps will be removed according to institutional standards of care, and the cecum must visualized; this may be done at the same time as the chromoendoscopy

Exclusion Criteria:

• Any history of rectal cancer; Exception: transanal excision without radiation

• Known diagnosis of colon heritable cancer syndrome (Familial adenomatous polyposis [FAP], hereditary nonpolyposis colorectal cancer [HNPCC]) or inflammatory bowel disease (Crohn's disease, ulcerative colitis)

• Inability to swallow capsules

• Bleeding diathesis

• Any invasive malignancy =< 5 years prior to pre-registration;

• Exceptions:

• patients with nonmelanoma skin cancers that were treated with simple excisional biopsy or stage I (T1,2 N0)

• colon cancer treated by endoscopic therapy or surgery are eligible

• History of gastroduodenal ulcers documented =< 1 year

• Known inability to participate in the scheduled follow-up tests

• Significant medical or psychiatric problems which would make the participant a poor protocol candidate, in the opinion of the treating physician

• Total colectomy

• Colostomy

• History of pelvic or rectal radiation therapy

• History of liver disease

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia

• Concomitant corticosteroids or anticoagulants needed on a regular or predictable intermittent basis

• Use of non-study investigational agent(s) =< 3 months prior to preregistration

• Chemotherapy =< 6 months prior to pre-registration; Note: Topical chemotherapy will be assessed on a case-by-case basis

• Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception Note: This study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown

• Over-the-counter green tea or green tea extract use =< 6 weeks prior to pre-registration; consumption of over the counter green tea extracts or drinking of green tea is not permitted during the treatment portion of this trial

• Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) =< 6 weeks prior to pre-registration; regular use of NSAIDs is defined as a frequency of 7 consecutive days (1 week) for > 3 weeks; participant must abstain from regular use of NSAIDs for the duration of the study; Exception: low dose aspirin (81 mg) for those participants who are chronic users of aspirin prior to the beginning of the study

• Use of non-study investigational agents while on study